{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:10:00Z","timestamp":1781712600395,"version":"3.54.5"},"reference-count":187,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Ministry for Science and Innovation","award":["PID2022-137222OB-I00"],"award-info":[{"award-number":["PID2022-137222OB-I00"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["PI21\/00568"],"award-info":[{"award-number":["PI21\/00568"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["2024\/27"],"award-info":[{"award-number":["2024\/27"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["FEHHJAN23\/001H"],"award-info":[{"award-number":["FEHHJAN23\/001H"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["imas12"],"award-info":[{"award-number":["imas12"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["PREP2022-000180"],"award-info":[{"award-number":["PREP2022-000180"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["CD22\/00009"],"award-info":[{"award-number":["CD22\/00009"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PID2022-137222OB-I00"],"award-info":[{"award-number":["PID2022-137222OB-I00"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00568"],"award-info":[{"award-number":["PI21\/00568"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["2024\/27"],"award-info":[{"award-number":["2024\/27"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FEHHJAN23\/001H"],"award-info":[{"award-number":["FEHHJAN23\/001H"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["imas12"],"award-info":[{"award-number":["imas12"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PREP2022-000180"],"award-info":[{"award-number":["PREP2022-000180"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD22\/00009"],"award-info":[{"award-number":["CD22\/00009"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRIS contra el C\u00e1ncer","award":["PID2022-137222OB-I00"],"award-info":[{"award-number":["PID2022-137222OB-I00"]}]},{"name":"CRIS contra el C\u00e1ncer","award":["PI21\/00568"],"award-info":[{"award-number":["PI21\/00568"]}]},{"name":"CRIS contra el C\u00e1ncer","award":["2024\/27"],"award-info":[{"award-number":["2024\/27"]}]},{"name":"CRIS contra el C\u00e1ncer","award":["FEHHJAN23\/001H"],"award-info":[{"award-number":["FEHHJAN23\/001H"]}]},{"name":"CRIS contra el C\u00e1ncer","award":["imas12"],"award-info":[{"award-number":["imas12"]}]},{"name":"CRIS contra el C\u00e1ncer","award":["PREP2022-000180"],"award-info":[{"award-number":["PREP2022-000180"]}]},{"name":"CRIS contra el C\u00e1ncer","award":["CD22\/00009"],"award-info":[{"award-number":["CD22\/00009"]}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["PID2022-137222OB-I00"],"award-info":[{"award-number":["PID2022-137222OB-I00"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["PI21\/00568"],"award-info":[{"award-number":["PI21\/00568"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["2024\/27"],"award-info":[{"award-number":["2024\/27"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["FEHHJAN23\/001H"],"award-info":[{"award-number":["FEHHJAN23\/001H"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["imas12"],"award-info":[{"award-number":["imas12"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["PREP2022-000180"],"award-info":[{"award-number":["PREP2022-000180"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009093","name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","award":["CD22\/00009"],"award-info":[{"award-number":["CD22\/00009"]}],"id":[{"id":"10.13039\/501100009093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre","award":["PID2022-137222OB-I00"],"award-info":[{"award-number":["PID2022-137222OB-I00"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre","award":["PI21\/00568"],"award-info":[{"award-number":["PI21\/00568"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre","award":["2024\/27"],"award-info":[{"award-number":["2024\/27"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre","award":["FEHHJAN23\/001H"],"award-info":[{"award-number":["FEHHJAN23\/001H"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre","award":["imas12"],"award-info":[{"award-number":["imas12"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre","award":["PREP2022-000180"],"award-info":[{"award-number":["PREP2022-000180"]}]},{"name":"Instituto de Investigaci\u00f3n Sanitaria 12 de Octubre","award":["CD22\/00009"],"award-info":[{"award-number":["CD22\/00009"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["PID2022-137222OB-I00"],"award-info":[{"award-number":["PID2022-137222OB-I00"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["PI21\/00568"],"award-info":[{"award-number":["PI21\/00568"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["2024\/27"],"award-info":[{"award-number":["2024\/27"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["FEHHJAN23\/001H"],"award-info":[{"award-number":["FEHHJAN23\/001H"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["imas12"],"award-info":[{"award-number":["imas12"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["PREP2022-000180"],"award-info":[{"award-number":["PREP2022-000180"]}]},{"name":"Spanish Ministry for Science and Innovation","award":["CD22\/00009"],"award-info":[{"award-number":["CD22\/00009"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PID2022-137222OB-I00"],"award-info":[{"award-number":["PID2022-137222OB-I00"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00568"],"award-info":[{"award-number":["PI21\/00568"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["2024\/27"],"award-info":[{"award-number":["2024\/27"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FEHHJAN23\/001H"],"award-info":[{"award-number":["FEHHJAN23\/001H"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["imas12"],"award-info":[{"award-number":["imas12"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PREP2022-000180"],"award-info":[{"award-number":["PREP2022-000180"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD22\/00009"],"award-info":[{"award-number":["CD22\/00009"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The maturation of B cells is a complex, multi-step process. During B cell differentiation, errors can occur, leading to the emergence of aberrant versions of B cells that, finally, constitute a malignant tumor. These B cell malignancies are classified into three main groups: leukemias, myelomas, and lymphomas, the latter being the most heterogeneous type. Since their discovery, multiple biological studies have been performed to characterize these diseases, aiming to define their specific features and determine potential biomarkers for diagnosis, stratification, and prognosis. The rise of advanced -omics approaches has significantly contributed to this end. Notably, proteomics strategies appear as promising tools to comprehensively profile the final molecular effector of these cells. In this narrative review, we first introduce the main B cell malignancies together with the most relevant proteomics approaches. Then, we describe the core studies conducted in the field and their main findings and, finally, we evaluate the advantages and drawbacks of flow cytometry, mass cytometry, and mass spectrometry for the profiling of human B cell disorders.<\/jats:p>","DOI":"10.3390\/ijms25094644","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T10:18:36Z","timestamp":1713953916000},"page":"4644","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5543-5154","authenticated-orcid":false,"given":"Cristina","family":"Jim\u00e9nez","sequence":"first","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca (HUS\/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1151-9566","authenticated-orcid":false,"given":"Alba","family":"Garrote-de-Barros","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, 28040 Madrid, Spain"},{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6947-9887","authenticated-orcid":false,"given":"Carlos","family":"L\u00f3pez-Portugu\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Physical and Analytical Chemistry Chemistry, Faculty of Chemistry, University of Oviedo, 33006 Oviedo, Spain"},{"name":"Health Research Institute of the Principality of Asturias (ISPA), 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, 28040 Madrid, Spain"},{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-6898","authenticated-orcid":false,"given":"Paula","family":"D\u00edez","sequence":"additional","affiliation":[{"name":"Department of Physical and Analytical Chemistry Chemistry, Faculty of Chemistry, University of Oviedo, 33006 Oviedo, Spain"},{"name":"Health Research Institute of the Principality of Asturias (ISPA), 33011 Oviedo, Spain"},{"name":"Department of Functional Biology, Faculty of Medicine and Health Science, University of Oviedo, 33006 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic Lymphocytic Leukemia: 2022 Update on Diagnostic and Therapeutic Procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible Diagnosis of Chronic Lymphocytic Leukemia by Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-Term Remissions after FCR Chemoimmunotherapy in Previously Untreated Patients with CLL: Updated Results of the CLL8 Trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-Line Chemoimmunotherapy with Bendamustine and Rituximab versus Fludarabine, Cyclophosphamide, and Rituximab in Patients with Advanced Chronic Lymphocytic Leukaemia (CLL10): An International, Open-Label, Randomised, Phase 3, Non-Inferiority Trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer Statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute Lymphoblastic Leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Riva, G., Nasillo, V., Ottomano, A.M., Bergonzini, G., Paolini, A., Forghieri, F., Lusenti, B., Barozzi, P., Lagreca, I., and Fiorcari, S. (2021). Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers, 13.","DOI":"10.3390\/cancers13184582"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High Frequency and Poor Outcome of Philadelphia Chromosome\u2013Like Acute Lymphoblastic Leukemia in Adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11790","DOI":"10.1038\/ncomms11790","article-title":"Identification of ETV6-RUNX1-like and DUX4-Rearranged Subtypes in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia","volume":"7","author":"Henningsson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.annonc.2023.09.3112","article-title":"ESMO Clinical Practice Guideline Interim Update on the Use of Targeted Therapy in Acute Lymphoblastic Leukaemia","volume":"35","author":"Hoelzer","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.2015.124016","article-title":"Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia","volume":"100","author":"Leoni","year":"2015","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1237031","DOI":"10.3389\/fonc.2023.1237031","article-title":"Positioning Blinatumomab in the Frontline of Adult B-Cell Acute Lymphoblastic Leukemia Treatment","volume":"13","author":"Pourhassan","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/1078155219895079","article-title":"Driving toward Precision Medicine for B Cell Lymphomas: Targeting the Molecular Pathogenesis at the Gene Level","volume":"26","author":"Chung","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/jmedsci.jmedsci_147_17","article-title":"Diffuse Large B-Cell Lymphoma-Review","volume":"38","author":"Singh","year":"2018","journal-title":"J. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and Etiology of Diffuse Large B-Cell Lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of Haematological Malignancy by Sub-Type: A Report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse Large B-Cell Lymphoma: 2019 Update on Diagnosis, Risk Stratification, and Treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/17512433.2019.1683447","article-title":"Novel Insights into the Pathogenesis of Molecular Subtypes of Diffuse Large B-Cell Lymphoma and Their Clinical Implications","volume":"12","author":"Frontzek","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3324\/haematol.2018.190157","article-title":"Inferior Survival in High-Grade B-Cell Lymphoma with MYC and BCL2 and\/or BCL6 Rearrangements Is Not Associated with MYC\/IG Gene Rearrangements","volume":"103","author":"McPhail","year":"2018","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse Large B Cell Lymphoma: A Review of Current Data and Potential Applications on Risk Stratification and Management","volume":"96","author":"Barta","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular Lymphoma: 2020 Update on Diagnosis and Management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20120015","article-title":"Follicular Lymphoma","volume":"34","author":"Luminari","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1172\/JCI72415","article-title":"Germinal Center Reentries of BCL2-Overexpressing B Cells Drive Follicular Lymphoma Progression","volume":"124","author":"Sungalee","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular Lymphoma: 2023 Update on Diagnosis and Management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/PLMI.S20709","article-title":"Flow Cytometric Immunophenotyping of Hematological Malignancies: The Way Forward in Nigeria","volume":"3","author":"Olaniyi","year":"2011","journal-title":"Pathol. Lab. Med. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cyto.b.22153","article-title":"Immunophenotypic Portrait of leukemia-associated-phenotype Markers in B Acute Lymphoblastic Leukemia","volume":"106","author":"Boris","year":"2024","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"112429","DOI":"10.1016\/j.jim.2018.03.005","article-title":"Differential Expression of CD73, CD86 and CD304 in Normal vs. Leukemic B-Cell Precursors and Their Utility as Stable Minimal Residual Disease Markers in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"475","author":"Theunissen","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1007\/s13277-014-1899-8","article-title":"Diagnostic Value of CD117 in Differential Diagnosis of Acute Leukemias","volume":"35","author":"Ahmadi","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jiang, Z., Wu, D., Lin, S., and Li, P. (2016). CD34 and CD38 Are Prognostic Biomarkers for Acute B Lymphoblastic Leukemia. Biomark. Res., 4.","DOI":"10.1186\/s40364-016-0080-5"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1182\/bloodadvances.2021005725","article-title":"Expert-Independent Classification of Mature B-Cell Neoplasms Using Standardized Flow Cytometry: A Multicentric Study","volume":"6","author":"Engelmann","year":"2022","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Paulus, A., Chitta, K.S., Wallace, P.K., Advani, P.P., Akhtar, S., Kuranz-Blake, M., Ailawadhi, S., and Chanan-Khan, A.A. (2015). Immunophenotyping of Waldenstr\u00f6ms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122338"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2007.06965.x","article-title":"CD49d Expression Is an Independent Predictor of Overall Survival in Patients with Chronic Lymphocytic Leukaemia: A Prognostic Parameter with Therapeutic Potential","volume":"140","author":"Shanafelt","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.htct.2019.07.006","article-title":"Multidisciplinary Diagnostics of Chronic Lymphocytic Leukemia: European Research Initiative on CLL\u2014ERIC Recommendations","volume":"42","author":"Zalcberg","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3748\/wjg.v17.i6.697","article-title":"Primary Gastrointestinal Lymphoma","volume":"17","author":"Ghimire","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1182\/blood.V120.21.5112.5112","article-title":"Clinicopathologic Significance of CD11c, CD16 and FOXP3 Expression in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Rituximab, Cyclophosphamide, Anthracycline, Vincristine, and Prednisolone (R-CHOP) Combination Chemotherapy","volume":"120","author":"Oh","year":"2012","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1182\/blood-2018-99-119031","article-title":"Circulating B Cell Subsets from Untreated Diffuse Large B Cell Lymphoma (DLBCL) Patients Resemble Those of Patients with Autoimmune Disease","volume":"132","author":"Koff","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1080\/1042819021000006385","article-title":"CD148 and CD27 Are Expressed in B Cell Lymphomas Derived from Both Memory and Na\u00efve B Cells","volume":"43","author":"Dong","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma","volume":"90","author":"Paiva","year":"2016","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_51","unstructured":"Lynch, D.T., Koya, S., Acharya, U., and Kumar, A. (2024). Mantle Cell Lymphoma, StatPearls."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle Cell Lymphoma in 2022-A Comprehensive Update on Molecular Pathogenesis, Risk Stratification, Clinical Approach, and Current and Novel Treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1590","DOI":"10.1002\/cnr2.1590","article-title":"Mantle Cell Lymphoma: A Clinical Review of the Changing Treatment Paradigms with the Advent of Novel Therapies, and an Insight into Indian Data","volume":"5","author":"Radhakrishnan","year":"2022","journal-title":"Cancer Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PAI.0b013e31825d550a","article-title":"Selective Immunophenotyping for Diagnosis of B-Cell Neoplasms: Immunohistochemistry and Flow Cytometry Strategies and Results","volume":"21","author":"Boyd","year":"2013","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly Diagnosed and Relapsed Mantle Cell Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of Marginal Zone Lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.beha.2016.08.025","article-title":"Marginal Zone Lymphoma in Elderly and Geriatric Patients","volume":"30","author":"Goede","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"406","DOI":"10.12688\/f1000research.13826.1","article-title":"Recent Advances in Understanding the Biology of Marginal Zone Lymphoma","volume":"7","author":"Bertoni","year":"2018","journal-title":"F1000Reserch"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.3152","article-title":"Marginal Zone Lymphomas","volume":"41","author":"Zucca","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2011.08877.x","article-title":"Burkitt Lymphoma in Adults","volume":"156","author":"Linch","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","article-title":"Burkitt Lymphoma","volume":"8","author":"Burkhardt","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13244-019-0733-7","article-title":"An Update on Burkitt Lymphoma: A Review of Pathogenesis and Multimodality Imaging Assessment of Disease Presentation, Treatment Response, and Recurrence","volume":"10","author":"Kalisz","year":"2019","journal-title":"Insights Imaging"},{"key":"ref_64","unstructured":"Graham, B.S., and Lynch, D.T. (2024). Burkitt Lymphoma, StatPearls."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CCO.0000000000000668","article-title":"CD19-Directed CAR T-Cell Therapy in B-Cell NHL","volume":"32","author":"Kersten","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/pds.3927","article-title":"Patient Population with Multiple Myeloma and Transitions across Different Lines of Therapy in the USA: An Epidemiologic Model","volume":"25","author":"Merinopoulou","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple Myeloma Epidemiology and Survival: A Unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 Patients with Newly Diagnosed Multiple Myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus Guidelines on Plasma Cell Myeloma Minimal Residual Disease Analysis and Reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1634\/theoncologist.6-2-119","article-title":"Update on the Treatment of Multiple Myeloma","volume":"6","author":"Kyle","year":"2001","journal-title":"Oncologist"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple Myeloma: Every Year a New Standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification and Management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/cncr.32177","article-title":"Recycling Therapies for Myeloma: The Need for Prospective Trials","volume":"125","author":"Kumar","year":"2019","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25117","article-title":"Multiple Myeloma: 2018 Update on Diagnosis, Risk-stratification, and Management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"x334","DOI":"10.1093\/annonc\/mds311","article-title":"How to Select among Available Options for the Treatment of Multiple Myeloma","volume":"23","author":"Harousseau","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2020009741","article-title":"The Protein Landscape of Chronic Lymphocytic Leukemia","volume":"138","author":"Lu","year":"2021","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1038\/s41467-022-33385-8","article-title":"Proteogenomics Refines the Molecular Classification of Chronic Lymphocytic Leukemia","volume":"13","author":"Herbst","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1756-8722-6-52","article-title":"Protein Biomarkers Distinguish between High- and Low-Risk Pediatric Acute Lymphoblastic Leukemia in a Tissue Specific Manner","volume":"6","author":"Braoudaki","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Cavalcante, M.d.S., Torres-Romero, J.C., Lobo, M.D.P., Moreno, F.B.M.B., Bezerra, L.P., Lima, D.S., Matos, J.C., Moreira, R.d.A., and Monteiro-Moreira, A.C.d.O. (2016). A Panel of Glycoproteins as Candidate Biomarkers for Early Diagnosis and Treatment Evaluation of B-Cell Acute Lymphoblastic Leukemia. Biomark. Res., 4.","DOI":"10.1186\/s40364-016-0055-6"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12079-016-0357-3","article-title":"Identification of Potential Predictive Markers of Dexamethasone Resistance in Childhood Acute Lymphoblastic Leukemia","volume":"11","author":"Omrani","year":"2017","journal-title":"J. Cell Commun. Signal"},{"key":"ref_83","first-page":"181","article-title":"Proteomic Changes in a Childhood Acute Lymphoblastic Leukemia Cell Line during the Adaptation to Vincristine","volume":"74","author":"Quezada","year":"2017","journal-title":"Bol. Med. Hosp. Infant. Mex."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-022-29224-5","article-title":"Integrative Multi-Omics and Drug Response Profiling of Childhood Acute Lymphoblastic Leukemia Cell Lines","volume":"13","author":"Leo","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12953-021-00184-w","article-title":"Identification and Validation of Serum Autoantibodies in Children with B-Cell Acute Lymphoblastic Leukemia by Serological Proteome Analysis","volume":"20","author":"Yu","year":"2022","journal-title":"Proteome Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1182\/blood-2019-126387","article-title":"Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype","volume":"134","author":"Stern","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"van der Meeren, L.E., Kluiver, J., Rutgers, B., Alsagoor, Y., Kluin, P.M., van den Berg, A., and Visser, L. (2019). A Super-SILAC Based Proteomics Analysis of Diffuse Large B-Cell Lymphoma-NOS Patient Samples to Identify New Proteins That Discriminate GCB and Non-GCB Lymphomas. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223260"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1080\/10428194.2021.1913147","article-title":"Proteomic Analysis in Diffuse Large B-Cell Lymphoma Identifies Dysregulated Tumor Microenvironment Proteins in Non-GCB\/ABC Subtype Patients","volume":"62","author":"Stern","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1074\/mcp.M400008-MCP200","article-title":"Quantitative Proteomic and Transcriptional Analysis of the Response to the P38 Mitogen-Activated Protein Kinase Inhibitor SB203580 in Transformed Follicular Lymphoma Cells","volume":"3","author":"Lin","year":"2004","journal-title":"Mol. Cell Proteom."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1074\/mcp.M500112-MCP200","article-title":"Analysis of BCL6-Interacting Proteins by Tandem Mass Spectrometry","volume":"4","author":"Miles","year":"2005","journal-title":"Mol. Cell Proteom."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jchromb.2009.02.071","article-title":"Development of a Sensitive and Selective LC\/MS\/MS Method for the Simultaneous Determination of Intracellular 1-Beta-D-Arabinofuranosylcytosine Triphosphate (AraCTP), Cytidine Triphosphate (CTP) and Deoxycytidine Triphosphate (DCTP) in a Human Follicular Lymphoma Cell Line","volume":"877","author":"Crauste","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jchromb.2008.10.036","article-title":"Quantitative Proteomic Analysis of Follicular Lymphoma Cells in Response to Rituximab","volume":"877","author":"Everton","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Du\u015b-Szachniewicz, K., Rymkiewicz, G., Agrawal, A.K., Ko\u0142odziej, P., and Wi\u015bniewski, J.R. (2021). Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis. Cancers, 13.","DOI":"10.3390\/cancers13040630"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1182\/bloodadvances.2023011299","article-title":"Proteomics Identifies Apoptotic Markers as Predictors of Histological Transformation in Patients with Follicular Lymphoma","volume":"7","author":"Enemark","year":"2023","journal-title":"Blood Adv."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1002\/elps.200600831","article-title":"Proteome- and Microarray-Based Expression Analysis of Lymphoma Cell Lines Identifies a P53-Centered Cluster of Differentially Expressed Proteins in Mantle Cell and Follicular Lymphoma","volume":"28","author":"Weinkauf","year":"2007","journal-title":"Electrophoresis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1477-5956-7-43","article-title":"A Comparison between Protein Profiles of B Cell Subpopulations and Mantle Cell Lymphoma Cells","volume":"7","author":"Stranneheim","year":"2009","journal-title":"Proteome Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1021\/pr801102c","article-title":"Proteomic Analysis of Malignant B-Cell Derived Microparticles Reveals CD148 as a Potentially Useful Antigenic Biomarker for Mantle Cell Lymphoma Diagnosis","volume":"8","author":"Miguet","year":"2009","journal-title":"J. Proteome Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/10428194.2010.549256","article-title":"Identification of Proteomic Signatures of Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, and Marginal Zone Lymphoma Biopsies by Surface Enhanced Laser Desorption\/Ionization-Time of Flight Mass Spectrometry","volume":"52","author":"Rolland","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/07357907.2013.820319","article-title":"The Use of Salivary Protein Secretions as an in Vivo Model to Study Mantel Cell Lymphoma Progression and Treatment","volume":"31","author":"Streckfus","year":"2013","journal-title":"Cancer Investig."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Lorkova, L., Scigelova, M., Arrey, T.N., Vit, O., Pospisilova, J., Doktorova, E., Klanova, M., Alam, M., Vockova, P., and Maswabi, B. (2015). Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135314"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen Presentation Profiling Reveals Recognition of Lymphoma Immunoglobulin Neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Psatha, K., Kollipara, L., Drakos, E., Deligianni, E., Brintakis, K., Patsouris, E., Sickmann, A., Rassidakis, G.Z., and Aivaliotis, M. (2023). Interruption of P53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level. Cancers, 15.","DOI":"10.3390\/cancers15153903"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2015.39","article-title":"Chlamydophila Psittaci-Negative Ocular Adnexal Marginal Zone Lymphomas Express Self Polyreactive B-Cell Receptors","volume":"29","author":"Zhu","year":"2015","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"30039","DOI":"10.18632\/oncotarget.15613","article-title":"Investigation of Three Potential Autoantibodies in Sjogren\u2019s Syndrome and Associated MALT Lymphoma","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The Whole-Genome Landscape of Burkitt Lymphoma Subtypes","volume":"134","author":"Panea","year":"2019","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"749095","DOI":"10.3389\/fphar.2022.749095","article-title":"Effect of Sophocarpine on the Pharmacokinetics of Umbralisib in Rat Plasma Using a Novel UPLC-MS\/MS Method","volume":"13","author":"Weng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2014.10.017","article-title":"Differential Proteomic Analysis of Endemic and Sporadic Epstein-Barr Virus-Positive and Negative Burkitt Lymphoma","volume":"51","author":"Day","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-Glycosylation of Monoclonal Light Chains on Routine MASS-FIX Testing Is a Risk Factor for MGUS Progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The Surfaceome of Multiple Myeloma Cells Suggests Potential Immunotherapeutic Strategies and Protein Markers of Drug Resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"101110","DOI":"10.1016\/j.xcrm.2023.101110","article-title":"A Target Discovery Pipeline Identified ILT3 as a Target for Immunotherapy of Multiple Myeloma","volume":"4","author":"Iyer","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow Antibody Panels for Standardized N-Dimensional Flow Cytometric Immunophenotyping of Normal, Reactive and Malignant Leukocytes","volume":"26","author":"Lhermitte","year":"2012","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"112662","DOI":"10.1016\/j.jim.2019.112662","article-title":"EuroFlow Lymphoid Screening Tube (LST) Data Base for Automated Identification of Blood Lymphocyte Subsets","volume":"475","author":"Grigore","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1038\/s41375-018-0164-3","article-title":"Residual Normal B-Cell Profiles in Monoclonal B-Cell Lymphocytosis versus Chronic Lymphocytic Leukemia","volume":"32","author":"Criado","year":"2018","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MPH.0000000000001008","article-title":"Neuropilin-1\/CD304 Expression by Flow Cytometry in Pediatric Precursor B-Acute Lymphoblastic Leukemia: A Minimal Residual Disease and Potential Prognostic Marker","volume":"40","author":"Abaza","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bcmd.2016.04.004","article-title":"Flow-Cytometry-Based Evaluation of Peripheral Blood Lymphocytes in Prognostication of Newly Diagnosed DLBCL Patients","volume":"59","author":"Rusak","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"755623","DOI":"10.3389\/fimmu.2021.755623","article-title":"Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma","volume":"12","author":"Lhomme","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cyto.b.21861","article-title":"Flow Cytometry Aneuploidy and Cell Cycle Indexing as a Possible Tool for Differentiating between CD10+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma","volume":"98","author":"Azoulay","year":"2020","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1309\/AJCP0XQDGKFR0HTW","article-title":"A Novel Flow Cytometric Antibody Panel for Distinguishing Burkitt Lymphoma from CD10+ Diffuse Large B-Cell Lymphoma","volume":"133","author":"Schniederjan","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_119","first-page":"5001","article-title":"Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa","volume":"37","author":"Kase","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 Expression and Complement Inhibitors Affect Response and Resistance to Daratumumab Therapy in Myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic Identification and Characterization of Granulocytic Myeloid-Derived Suppressor Cells in Multiple Myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Carvalho, A.S., Baeta, H., Henriques, A.F.A., Ejtehadifar, M., Tranfield, E.M., Sousa, A.L., Farinho, A., Silva, B.C., Cabe\u00e7adas, J., and Gameiro, P. (2021). Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011004"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-021-03162-2","article-title":"Expression of Activated Integrin \u03927 in Multiple Myeloma Patients","volume":"114","author":"Hosen","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"338672","DOI":"10.1016\/j.aca.2021.338672","article-title":"Combinatory Strategy Using Nanoscale Proteomics and Machine Learning for T Cell Subtyping in Peripheral Blood of Single Multiple Myeloma Patients","volume":"1173","author":"Ye","year":"2021","journal-title":"Anal. Chim. Acta"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e1465167","DOI":"10.1080\/2162402X.2018.1465167","article-title":"High-Dimensional Mass Cytometry Analysis Revealed Microenvironment Complexity in Chronic Lymphocytic Leukemia","volume":"7","author":"Wierz","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1020740","DOI":"10.3389\/fonc.2022.1020740","article-title":"Mass Cytometry Analysis Reveals Attrition of Na\u00efve and Anergized Self-Reactive Non-Malignant B Cells in Chronic Lymphocytic Leukemia Patients","volume":"12","author":"Andrieu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/cyto.a.23919","article-title":"Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity","volume":"97","author":"Nissen","year":"2020","journal-title":"Cytom. A"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Ferrant, J., Le Gallou, S., Padonou, F., L\u00e9onard, S., Papa, I., Pangault, C., Barthel, A., Launay, V., Manson, G., and Hoareau, B. (2022). Single-Cell Profiling Identifies Clinically Relevant Interactions between Tumor Associated Macrophages and Blood Endothelial Cells in Diffuse Large B Cell Lymphoma. bioRxiv.","DOI":"10.1101\/2022.12.08.519637"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/JLB.6MA0822-720RR","article-title":"Single-Cell Phenotypic Profiling to Identify a Set of Immune Cell Protein Biomarkers for Relapsed and Refractory Diffuse Large B Cell Lymphoma: A Single-Center Study","volume":"112","author":"Shi","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Lei, T., Wu, G., Xu, Y., Zhuang, W., Lu, J., Han, S., Zhuang, Y., Dong, X., and Yang, H. (2023). Peripheral Immune Cell Profiling of Double-Hit Lymphoma by Mass Cytometry. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10657-0"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/2326-6066.CIR-14-0236-T","article-title":"Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma","volume":"3","author":"Hansmann","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-019-0234-4","article-title":"Mass Cytometry Dissects T Cell Heterogeneity in the Immune Tumor Microenvironment of Common Dysproteinemias at Diagnosis and after First Line Therapies","volume":"9","author":"Kourelis","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e01132","DOI":"10.1002\/cti2.1132","article-title":"Identification of the Immune Checkpoint Signature of Multiple Myeloma Using Mass Cytometry-Based Single-Cell Analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2022007905","article-title":"NK Cells CD56bright and CD56dim Subset Cytokine Loss and Exhaustion Is Associated with Impaired Survival in Myeloma","volume":"6","author":"Seymour","year":"2022","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e159924","DOI":"10.1172\/jci.insight.159924","article-title":"Heterogeneity of B Cell Lymphopoiesis in Patients with Premalignant and Active Myeloma","volume":"8","author":"Jakubikova","year":"2023","journal-title":"JCI Insight"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1085893","DOI":"10.3389\/fimmu.2023.1085893","article-title":"Multi-Omic Analysis of the Tumor Microenvironment Shows Clinical Correlations in Ph1 Study of Atezolizumab +\/\u2212 SoC in MM","volume":"14","author":"Wong","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-023-00851-5","article-title":"Mass Cytometry Reveals Unique Phenotypic Patterns Associated with Subclonal Diversity and Outcomes in Multiple Myeloma","volume":"13","author":"Baughn","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-022-00623-7","article-title":"Proteomic Profiling Based Classification of CLL Provides Prognostication for Modern Therapy and Identifies Novel Therapeutic Targets","volume":"12","author":"Griffen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-05-0637","article-title":"Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma","volume":"11","author":"Gulmann","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e1524","DOI":"10.1002\/cnr2.1524","article-title":"Serum Proteome Modulations upon Treatment Provides Biological Insight on Response to Treatment in Relapsed Mantle Cell Lymphoma","volume":"5","author":"Lokhande","year":"2022","journal-title":"Cancer Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1074\/mcp.M800515-MCP200","article-title":"Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma","volume":"8","author":"Boyd","year":"2009","journal-title":"Mol. Cell Proteom."},{"key":"ref_144","unstructured":"Jiang, Y., Rex, D.A.B., Schuster, D., Neely, B.A., Rosano, G.L., Volkmar, N., Momenzadeh, A., Peters-Clarke, T.M., Egbert, S.B., and Kreimer, S. (2023). Comprehensive Overview of Bottom-Up Proteomics Using Mass Spectrometry. arXiv."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"van Bergen, W., Heck, A.J.R., and Baggelaar, M.P. (2022). Recent Advancements in Mass Spectrometry-Based Tools to Investigate Newly Synthesized Proteins. Curr. Opin. Chem. Biol., 66.","DOI":"10.1016\/j.cbpa.2021.07.001"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1021\/acs.chemrev.1c00212","article-title":"High-Resolution Native Mass Spectrometry","volume":"122","author":"Tamara","year":"2022","journal-title":"Chem. Rev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/mas.21670","article-title":"Surface-Assisted Laser Desorption\/Ionization Mass Spectrometry Imaging: A Review","volume":"41","author":"Verdin","year":"2022","journal-title":"Mass. Spectrom. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1021\/jp304709q","article-title":"Analysis of Initial Reactions of MALDI Based on Chemical Properties of Matrixes and Excitation Condition","volume":"116","author":"Lai","year":"2012","journal-title":"J. Phys. Chem. B"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/mas.21520","article-title":"Time-of-Flight Mass Spectrometry: Introduction to the Basics","volume":"36","author":"Boesl","year":"2017","journal-title":"Mass. Spectrom. Rev."},{"key":"ref_150","unstructured":"Pareige, C., Lefebvre-Ulrikson, W., Vurpillot, F., and Sauvage, X. (2016). Atom Probe Tomography, Elsevier."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acs.accounts.3c00079","article-title":"Orbitrap-Based Mass and Charge Analysis of Single Molecules","volume":"56","author":"Rolland","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/ac4001223","article-title":"Orbitrap Mass Spectrometry","volume":"85","author":"Zubarev","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jasms.2007.11.013","article-title":"Hybrid Mass Spectrometers for Tandem Mass Spectrometry","volume":"19","author":"Glish","year":"2008","journal-title":"J. Am. Soc. Mass. Spectrom."},{"key":"ref_154","first-page":"20150366","article-title":"Quantitative Mass Spectrometry Methods for Pharmaceutical Analysis","volume":"374","author":"Loos","year":"2016","journal-title":"Philos. Trans. A Math. Phys. Eng. Sci."},{"key":"ref_155","first-page":"pdb.prot4728","article-title":"Isotope-Coded Affinity Tagging of Proteins","volume":"2007","author":"Aebersold","year":"2007","journal-title":"CSH Protoc."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-4939-3759-2_17","article-title":"Isobaric Tag for Relative and Absolute Quantitation (ITRAQ)-Based Protein Profiling in Plants","volume":"1450","author":"Wen","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/pmic.201500108","article-title":"Quantitative Proteomics Using SILAC: Principles, Applications, and Developments","volume":"15","author":"Chen","year":"2015","journal-title":"Proteomics"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1074\/mcp.TIR119.001385","article-title":"TMT Labeling for the Masses: A Robust and Cost-Efficient, In-Solution Labeling Approach","volume":"18","author":"Zecha","year":"2019","journal-title":"Mol. Cell Proteom."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e9266","DOI":"10.1002\/rcm.9266","article-title":"Resolving Isobaric Interferences in Direct Infusion Tandem Mass Spectrometry","volume":"36","author":"Kaeslin","year":"2022","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Cortese, M., Gigliobianco, M.R., Magnoni, F., Censi, R., and Di Martino, P. (2020). Compensate for or Minimize Matrix Effects? Strategies for Overcoming Matrix Effects in Liquid Chromatography-Mass Spectrometry Technique: A Tutorial Review. Molecules, 25.","DOI":"10.3390\/molecules25133047"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5.1.1","DOI":"10.1002\/cpim.40","article-title":"Flow Cytometry: An Overview","volume":"120","author":"McKinnon","year":"2018","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cyto.a.24566","article-title":"The Evolution of Spectral Flow Cytometry","volume":"101","author":"Nolan","year":"2022","journal-title":"Cytom. Part A"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/eji.201646632","article-title":"Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological Studies*","volume":"47","author":"Cossarizza","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.04.019","article-title":"Mass Cytometry: Single Cells, Many Features","volume":"165","author":"Spitzer","year":"2016","journal-title":"Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cels.2018.02.010","article-title":"Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry","volume":"6","author":"Chevrier","year":"2018","journal-title":"Cell Syst."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.immuni.2021.03.019","article-title":"Immunometabolism the CyTOF Way","volume":"54","author":"Qian","year":"2021","journal-title":"Immunity"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.eng.2021.06.022","article-title":"Applications of CyTOF in Brain Immune Component Studies","volume":"16","author":"Wang","year":"2022","journal-title":"Engineering"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/1947-2714.100998","article-title":"Western Blot: Technique, Theory, and Trouble Shooting","volume":"4","author":"Mahmood","year":"2012","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_169","unstructured":"Lourido, L., Diez, P., Dasilva, N., Gonzalez-Gonzalez, M., Ruiz-Romero, C., Blanco, F., Orfao, A., LaBaer, J., and Fuentes, M. (2014). Genomics and Proteomics for Clinical Discovery and Development, Springer."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"114992","DOI":"10.1016\/j.addr.2023.114992","article-title":"Omics Approaches for the Assessment of Biological Responses to Nanoparticles","volume":"200","author":"Abdelkader","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41374-022-00830-7","article-title":"High-Throughput Proteomics: A Methodological Mini-Review","volume":"102","author":"Cui","year":"2022","journal-title":"Lab. Investig."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14789450.2021.1976152","article-title":"Phosphoproteomics: A Valuable Tool for Uncovering Molecular Signaling in Cancer Cells","volume":"18","author":"Gerritsen","year":"2021","journal-title":"Expert Rev. Proteom."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"433","DOI":"10.14348\/molcells.2021.0042","article-title":"Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes","volume":"44","author":"Heo","year":"2021","journal-title":"Mol. Cells"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1038\/bcj.2015.49","article-title":"The Cellular Immune System in Myelomagenesis: NK Cells and T Cells in the Development of MM and Their Uses in Immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"613007","DOI":"10.3389\/fimmu.2020.613007","article-title":"PD-L1\/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients","volume":"11","author":"Costa","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7812\/TPP\/21.081","article-title":"Chronic Lymphocytic Leukemia With Leptomeningeal Involvement Presenting as an Acute Encephalopathy","volume":"26","author":"Bae","year":"2022","journal-title":"Perm. J."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e32567","DOI":"10.1097\/MD.0000000000032567","article-title":"Primary Meningeal Central Nervous System Lymphoma: A Case Report and Literature Review","volume":"101","author":"Chen","year":"2022","journal-title":"Medicine"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/cyto.b.21227","article-title":"The Utility of Multiparametric Seven-color Flow Cytometry in the Detection of Double Hit Lymphoma in Ascitic Fluid Samples","volume":"90","author":"Cordoba","year":"2016","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e04657","DOI":"10.1002\/ccr3.4657","article-title":"Early Complete Response of Primary Bone Marrow B-cell Lymphoma Treated with Rituximab-based CHOP Therapy, Assessed by Flow Cytometry and Immunogloblin Heavy Chain Rearrangement","volume":"9","author":"Nabe","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1479-5876-9-188","article-title":"Correspondence between Salivary Proteomic Pattern and Clinical Course in Primary Sj\u00f6gren Syndrome and Non-Hodgkin\u2019s Lymphoma: A Case Report","volume":"9","author":"Baldini","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7705\/biomedica.6779","article-title":"Geotricosis: Fungemia En Paciente Con Leucemia Linfobl\u00e1stica Aguda","volume":"43","author":"Reyes","year":"2023","journal-title":"Biom\u00e9dica"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2169\/internalmedicine.2082-18","article-title":"Exophiala dermatitidis Fungemia Diagnosed Using Time-of-Flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole","volume":"58","author":"Yoshida","year":"2019","journal-title":"Intern. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1016\/j.ijid.2013.03.005","article-title":"Breakthrough Bacteremia Due to Clostridium Tertium in a Patient with Neutropenic Fever, and Identification by MALDI-TOF Mass Spectrometry","volume":"17","author":"Salvador","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7754\/Clin.Lab.2021.210723","article-title":"Fatal Prototheca Zopfii Algaemia in a Patient with Acute Lymphoblastic Leukemia: A Case Report","volume":"68","author":"Kim","year":"2022","journal-title":"Clin. Lab."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1191992","DOI":"10.3389\/fimmu.2023.1191992","article-title":"Performance of Spectral Flow Cytometry and Mass Cytometry for the Study of Innate Myeloid Cell Populations","volume":"14","author":"Khatri","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Budnik, B., Levy, E., Harmange, G., and Slavov, N. (2018). SCoPE-MS: Mass Spectrometry of Single Mammalian Cells Quantifies Proteome Heterogeneity during Cell Differentiation. Genome Biol., 19.","DOI":"10.1186\/s13059-018-1547-5"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4644\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:33:29Z","timestamp":1760106809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":187,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094644"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094644","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]}}}